secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-06-04T20:08:29+00:00
Accession:  0001193125-26-257394
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics stockholders elect three Class I directors at 2026 annual meeting
--------------------------------------------------------------------------------

- Elected G. Clare Kahn, Ph.D. (49,722,339 for), Adrian Krainer, Ph.D. (36,531,612 for), and Julie Anne Smith (43,500,649 for) as Class I directors.
- Ratified Ernst & Young LLP as independent auditor for FY 2026 with 55,121,163 votes for, 2,036 against.
- Advisory vote on named executive officer compensation passed: 36,436,275 for, 13,565,293 against, 29,415 abstaining.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/0001193125-26-257394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526257394/d15052d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer